Halozyme Therapeutics

Latest news

• Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks (opens in a new tab)

  Yahoo Finance · Oct 1, 2026

• Argus raises target for Halozyme Therapeutics stock to USD 127 (opens in a new tab)

  AD HOC NEWS · Oct 1, 2026

• Halozyme Therapeutics Adds James Daly to Board (opens in a new tab)

  tipranks.com · Sep 30, 2026

• Halozyme appoints Jim Daly to board of directors By Investing.com (opens in a new tab)

  Investing.com Nigeria · Sep 30, 2026

• Halozyme adds James Daly to its Board of Directors (opens in a new tab)

  TradingView · Sep 30, 2026

• Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors (opens in a new tab)

  marketscreener.com · Sep 30, 2026

• Halozyme Announces Appointment of Jim Daly to its Board of Directors (opens in a new tab)

  PR Newswire · Sep 30, 2026

• Basic earnings per share (basic EPS) of Halozyme Therapeutics, Inc. – HAN:RV7 (opens in a new tab)

  TradingView · Sep 29, 2026

• Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) (opens in a new tab)

  TradingView · Sep 29, 2026

• ETFs Investing in Halozyme Therapeutics, Inc. Stocks (opens in a new tab)

  TradingView · Sep 29, 2026

• Halozyme Therapeutics (HALO) Closes A US$1.3b Note Offering, Is The Upside Already Priced In? (opens in a new tab)

  Simply Wall Street · Sep 24, 2026

• Halozyme stock falls 2.34% after strong quarterly growth (opens in a new tab)

  AD HOC NEWS · Sep 23, 2026

• Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? (opens in a new tab)

  Yahoo Finance · Sep 23, 2026

• If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (opens in a new tab)

  Yahoo Finance · Sep 23, 2026

• Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com (opens in a new tab)

  Investing.com India · Sep 22, 2026

• Halozyme Therapeutics completes $1.5 billion convertible notes offering (opens in a new tab)

  Investing.com · Sep 22, 2026

• Halozyme (HALO) Just Made A $1.3B Bet On Itself (opens in a new tab)

  Yahoo Finance · Sep 21, 2026

• Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk (opens in a new tab)

  AD HOC NEWS · Sep 20, 2026

• Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost? (opens in a new tab)

  Yahoo Finance · Sep 20, 2026

• Should Enlarged Notes Sale Require Action From Halozyme Therapeutics (HALO) Investors? (opens in a new tab)

  Simply Wall Street · Sep 19, 2026

• Halozyme prices $1.3B of 1.50% convertible notes due 2033, upsized with $200M option (opens in a new tab)

  TradingView · Sep 18, 2026

• Dynatrace, Cava Group, Halozyme Therapeutics (opens in a new tab)

  TradingView · Sep 18, 2026

• Halozyme Prices $1.3 Billion Convertible Senior Notes Offering (opens in a new tab)

  Yahoo Finance · Sep 18, 2026

• Halozyme Therapeutics stock hits all-time high at 111.56 USD (opens in a new tab)

  Investing.com · Sep 18, 2026

• Halozyme Therapeutics, Inc. (NASDAQ:HALO) Prices Upsized $1.3B 1.50% Convertible Notes Due 2033 (opens in a new tab)

  TradingView · Sep 17, 2026

• Halozyme prices $1.3B convertible notes to fund repurchases and growth initiatives (opens in a new tab)

  Pluang · Sep 17, 2026

• Halozyme prices $1.3B convertible senior notes offering due 2033 (opens in a new tab)

  TradingView · Sep 17, 2026

• Halozyme prices $1.3 billion convertible notes offering (opens in a new tab)

  Investing.com · Sep 17, 2026

• Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 (opens in a new tab)

  PR Newswire · Sep 17, 2026

• Is Halozyme Therapeutics (HALO) Fully Valued As Growth Calls And Partnerships Draw Fresh Attention? (opens in a new tab)

  Simply Wall Street · Sep 17, 2026